Open AccessA new intranasal therapy (MP29‐02*) is more effective than current firstline therapy regardless of season, symptom or severity.
Author(s) -
Bachert Claus,
Fokkens Wytske,
Hellings Peter,
Scadding Glenis,
Munzel Ullrich,
Mullol Joaquim
Publication year - 2015
Publication title -
clinical and translational allergy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.979
H-Index - 37
ISSN - 2045-7022
DOI - 10.1186/2045-7022-5-s4-p38
Subject(s) - medicine , fluticasone propionate , post hoc analysis , nasal congestion , placebo , clinical endpoint , azelastine , randomized controlled trial , fluticasone , anesthesia , surgery , nose , corticosteroid , alternative medicine , pathology
Background Moderate-to-severe allergic rhinitis (AR) is often poorly controlled. Patients remain symptomatic on treatment, despite multiple therapies. A more effective treatment is needed. We assessed the efficacy of MP29-02* (a novel intranasal formulation of azelastine hydrochloride (AZE) and fluticasone propionate (FP) in an advanced delivery system) during different seasons and for different symptoms and severities vs AZE, FP or placebo (PLA).